ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1424	National Cancer Institute	Html	en	Liver (Hepatocellular) Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer.	positive predictive value 0.503935 Needle aspiration cytology 0.492344 10-year survival rates 0.485559 hepatitis B virus 0.608203 hepatitis G infection 0.516552 control group 0.576587 6-monthly AFP assays 0.575205 North America 0.429041 nonalcoholic steatohepatitis 0.42282 AFP screening 0.526835 usual-care group 0.429439 ethnic groups 0.421496 test result 0.419937 HCC 0.942449 screening group 0.63461 Age-standardized incidence rates 0.541219 hepatitis B infection 0.498394 glycogen storage disease 0.517803 porphyria cutanea tarda 0.523911 new cases 0.427232 patients experience pain 0.502381 Serum AFP 0.49956 fetal-specific glycoprotein antigen 0.51455 United States 0.614175	screening tests 0.450593 retrospective case-control study 0.516703 mortality rate ratio 0.509505 certain Aspergillus species 0.510442 widely used tumor 0.501438 cryptogenic cirrhosis 0.452869 earlier diagnosis 0.555097 right upper quadrant 0.485875 common cancer 0.432709 surface antigen–positive carriers 0.524371 diagnosis study designs. 0.509206 Chinese Americans 0.422068 high incidence 0.419907 distinct male preponderance 0.54002 risk factor 0.421115 HCC mortality 0.712636 mortality rate 0.512472 randomized controlled trial 0.492498 alcoholic cirrhosis 0.45216 chronic hepatitis 0.816099 germ cell tumors 0.509004 liver biopsy 0.576034 annual risk 0.42449 liver cancer 0.48682	CLICK HERE
1453	National Cancer Institute	Html	en	Esophageal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing esophageal cancer and about research aimed at the prevention of this disease.	population-based case-controlled study 0.456088 Incidence rates 0.385333 symptomatic gastroesophageal reflux 0.449595 Barrett epithelium 0.458468 control group 0.467545 population attributable risk 0.450158 abnormal intestinal-type epithelium 0.466177 upper gastrointestinal hemorrhage 0.4271 GERD symptoms 0.44816 dysplastic Barrett esophagus 0.622479 distal esophagus 0.516913 case-control studies 0.466408 characteristic endoscopic appearance 0.435919 racial/ethnic groups 0.387576 alcohol abuse 0.441548 sham ablation 0.397202 patients 0.529714 incidence rate 0.442768 relative risk 0.448332 long-standing GERD 0.393778 esophageal adenocarcinoma 0.436843 esophageal adenocarcinoma. 0.389793 Retrospective cohort studies 0.444668 radiofrequency ablation 0.397459	new cases 0.385134 population-based cohort study 0.450776 esophageal cancer 0.543708 United States 0.381547 neoplastic alteration 0.380441 squamous epithelium. 0.390253 Barrett esophagus 0.930056 disease progression 0.441468 low-grade dysplasia 0.40734 significantly increased risk 0.448898 recurrent reflux symptoms 0.445059 important epidemiological difference 0.443496 black men 0.381968 case-control study 0.397548 high-grade dysplasia group 0.469185 adenocarcinoma 0.464553 certain GERD symptoms 0.4422 risk factor 0.383382 randomized controlled trial 0.433019 treatment group 0.414938 stratified squamous epithelium 0.484787 ablation group 0.497322 risk 0.45334 columnar epithelium 0.407571	CLICK HERE
1558	National Cancer Institute	Html	en	Endometrial Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease.	cancer treatment 0.459672 cancer prevention trials 0.519855 estrogen 0.503683 endometrial cancer prevention 0.633127 protective factors 0.494311 following PDQ summaries 0.487054 PDQ cancer information 0.583616 estrogen receptor modulators 0.479388 oral contraceptives increases 0.455046 uterus 0.455824 clinical trials 0.591442 cancer information summary 0.536389 breast cancer prevention 0.515055 cancer patients 0.456862 cancer risk factor 0.514935 NCI’s PDQ 0.460213 metabolic syndrome 0.469608 Clinical Trials section 0.455747 NCI PDQ cancer 0.511939 endometrial hyperplasia 0.525569 hormone replacement therapy 0.4814 new cases 0.45495 estrogen levels 0.496361 cancer risk factors 0.513284	Cancer prevention 0.648371 cancer protective factor 0.491722 high estrogen levels 0.479463 Cancer Information Service 0.48404 polycystic ovary syndrome 0.484739 prevention clinical trials 0.493334 Prevention Editorial Board 0.485326 treatment clinical trials 0.456257 National Cancer Institute 0.542099 endometrial cancer 0.951484 African American women 0.525683 estrogen therapy 0.459908 higher risk 0.454955 postmenopausal women 0.557323 Cancer Care page 0.476271 PDQ database 0.456704 PDQ summary 0.495085 combination oral contraceptives 0.477913 cancer clinical trials 0.489805 risk factors 0.587492 nonpolyposis colon cancer 0.481746 cancer information summaries 0.48866 comprehensive cancer information 0.488387 risk 0.63452	CLICK HERE
1881	National Cancer Institute	Html	es	Tratamiento del sarcoma de Ewing (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del Sarcoma de Ewing.	ewing sarcoma 0.997403 Ewing family 0.318421 Ewing's sarcoma family 0.369762 metastatic ewing sarcoma 0.318472 ewing óseo valor 0.311245 skeletal localized ewing 0.310397 Ewing Grupo 0.309837 non-metastatic ewing 0.310313 Ewing's Sarcoma Studies 0.319442 ewing óseo característica 0.311302 Ewing extraóseo 0.331665 Ewing sarcoma demonstrates 0.319966 Ewing sarcoma with 0.320002 localized ewing tumours 0.310538 localized ewing 0.369471 ewing-like sarcomas 0.313809 Children's Oncology Group 0.332597 ewing sarcoma family 0.424972 Ewing sarcoma patients 0.320654 with ewing 0.35586 Ewing's tumors with 0.311931 Ewing Sarcoma Study 0.321953 with localized ewing 0.320841 primary ewing 0.310256 extraskeletal ewing sarcoma 0.318994	Ewing's Sarcoma Study 0.335323 synovial sarcoma 0.309759 cooperative ewing sarcoma 0.431437 Ewing sarcoma under 0.319395 EWSR1-rearranged Ewing 0.309748 localized ewing tumor 0.320103 ewing extraóseo sarcoma 0.320923 osseous ewing 0.30998 Pediatr Blood Cancer 0.363663 ewing sarcoma defines 0.332159 Intergroup Cooperative Ewing 0.343374 Ewing Sarcoma Studies 0.337882 Genes Chromosomes Cancer 0.320148 ewing's sarcoma 0.626467 Ewing óseo 0.324425 gen ewsr1 0.309831 ewing's tumors 0.326472 secondary ewing 0.310067 Pediatr Hematol Oncol 0.310262 Clin Oncol 0.365031 multifocal ewing sarcoma 0.318953 ewing tumors 0.399514 congenital ewing sarcoma 0.318921 Ewing sarcoma susceptibility 0.318556	CLICK HERE
1991	National Cancer Institute	Html	es	Tratamiento del tumor teratoideo/rabdoide atípico del sistema nervioso central infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores teratoideos/rabdoides atípicos del sistema nervioso central infantil	Children’s Cancer Group 0.214389 Brain Tumor Registry 0.228944 Blaney S 0.21303 tumor or malignant 0.212972 highly malignant tumor 0.212766 CNS atypical teratoid 0.213711 nervous system atypical 0.507412 childhood atypical teratoid 0.213555 Instituto Nacional 0.211549 renal rhabdoid tumor 0.229121 teratoid rhabdoid tumours 0.215084 central nervous system 0.954132 rhabdoid tumors 0.527901 atypical teratoid 0.31284 nervous system malignant 0.215465 malignant rhabdoid tumor 0.241559 non-rhabdoid tumor with 0.213028 brain tumor consortium 0.236375 with central nervous 0.221866 Pediatric MATCH 0.208336 system atypical teratoid 0.255953 Children’s Oncology Group 0.209584 Cribriform neuroepithelial tumor 0.211375 with newly 0.207496 teratoid rhabdoid tumors 0.315276	Pediatr Blood Cancer 0.255454 Genes Chromosomes Cancer 0.225267 National Cancer Institute 0.207929 chemotherapy with autologous 0.210383 PDQ Tratamiento 0.209709 Tumor Registry 0.24792 Packer RJ 0.213353 tumor consortium study 0.212376 Pediatr Hematol Oncol 0.251621 Clin Oncol 0.239466 sistema nervioso central 0.330207 patient with 0.207449 brain tumor 0.273366 Pediatric Oncology Group 0.209965 with autologous hematopoietic 0.20843 Germline INI1 mutation 0.207759 with relapsed or 0.208722 término tumor 0.213201 atypical teratoid tumor 0.230394 newly diagnosed 0.211587 Austrian Brain Tumor 0.226397 Oncology Group 0.212124 tumor showing retained 0.210972 pediatric brain tumor 0.239731	CLICK HERE
2036	National Cancer Institute	Html	es	Tratamiento de las neoplasias mieloproliferativas crónicas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mieloproliferativas crónicas.	siguientes procedimientos 0.417826 células madre 0.649424 siguientes aspectos 0.405563 leucemia aguda 0.417682 cuerpo.ampliar trasplante 0.403016 hueso compacto 0.418199 genes mpl 0.404719 enlace drugs approved 0.416336 célula madre mieloide 0.431519 genes jak2 0.404899 Sudores nocturnos 0.404299 células anormales.ampliar aspiración 0.420044 National Cancer Institute 0.401966 siguientes riesgos 0.401801 Instituto Nacional 0.403647 célula madre linfoide 0.432844	PDQ Tratamiento 0.431983 leucemia mielógena 0.471893 Drugs Approved 0.417258 Physician Data Query 0.407937 llamada mielofibrosis 0.427648 serios problemas 0.403469 Myeloproliferative Neoplasms 0.417257 siguientes sustancias 0.403598 policitemia vera 0.696975 leucemia mieloide aguda 0.414565 gen jak2 0.405058 célula madre 0.501376 células sanguíneas maduras 0.468721 neoplasias mieloproliferativas 0.925417 siguientes pruebas 0.407534	CLICK HERE
2071	National Cancer Institute	Html	es	Cirugía para reducir el riesgo de cáncer de seno	Hoja informativa que describe las clases de cirugía para reducir el riesgo de cáncer de seno y las situaciones en las que se puede pensar en esas operaciones.	Surgical Adjuvant Breast 0.526694 PROSE Study Group 0.516256 cáncer invasor 0.567762 brca1 or brca2 0.538495 mastectomía subcutánea 0.530865 Preventing breast 0.511838 Breast Cancer Research 0.523551 risk-reducing surgery 0.507962 with brca1 or 0.509298 brca2 mutation 0.564149 breast screening with 0.51472 Preventive Services Task 0.512338 mastectomy reduces breast 0.516804 alta penetrancia 0.508455 risk after smaller 0.509063 Friebel T 0.508008 PubMed Abstract 0.952028 Clinical Oncology 0.653359 Cancer Journal 0.515034 BRCA2 mutation carriers 0.554396 early breast cancer 0.539203 ¿Cuáles mujeres 0.517292 bilateral mastectomy 0.517477 BRCA2 mutations detected 0.508495 alto riesgo 0.656597	Wickerham DL 0.51571 an overview 0.508367 Costantino JP 0.515178 Cancer Risk Assessment 0.519342 Rebbeck TR 0.508232 developing invasive breast 0.513495 antecedentes familiares 0.554456 riesgo promedio 0.539499 or brca2 mutations 0.536318 breast cancer risk 0.617067 mutation carriers with 0.509322 gen pten 0.510383 breast cancer 0.801718 Breast Cancer Trialists 0.522907 Services Task Force 0.511925 prophylactic mastectomy 0.591377 mujeres portadoras 0.533011 gen brca1 0.561202 contralateral prophylactic mastectomy 0.534028 Cancer Institute 0.511805 Clinical Cancer Research 0.516971 gen brca2 0.561192 gen tp53 0.518098 New England Journal 0.535054	CLICK HERE
3518	National Cancer Institute	Html	en	Use of Placebos	Information about placebos and their role in cancer clinical trials.	new treatment 0.545554 study 0.364583 patients 0.362034 medicine 0.367624 way 0.414648 treatment group 0.529513 to. 0.361225	doctors 0.371883 treatment clinical trials 0.815475 bias 0.382394 Placebos 0.570523 standard treatment 0.968379 cancer 0.37398	CLICK HERE
3676	National Cancer Institute	Html	en	Genomic Data Access	Information for NIH staff and extramural investigators on how to get a dbGaP account and how to request controlled-access data.	Supplementary Instructions 0.508326 trainees 0.351501 data use limitations 0.53645 access request form 0.751577 permanent employees 0.518968 cancer genotype-phenotype studies 0.653287 dbgap datasets 0.7932 Laboratory staff 0.513494 dbGaP Project Request 0.758272 Minimum Qualifications 0.520392 institution 0.370914 staff member 0.507438 database 0.339571 oversight 0.341561 responsibilities 0.337646 Extramural investigators 0.646629 postdoctoral fellows 0.532793 eRA Commons 0.541518 Applicants 0.337875 laboratory administration 0.514783 data access request 0.968754 NIH staff 0.519235 PIs 0.358599	tenure-track professor 0.518153 NCI Data Access 0.741329 signature approvals 0.518117 Eligibility requirements 0.511168 results 0.339375 email 0.333649 dbGaP Authorized Access 0.761069 seniorscientist 0.335515 Access Individual-Level Data 0.77002 principal investigators 0.705009 genotypes 0.422884 pre-existing account 0.549785 data access requests 0.732725 dbGaP Request Procedures 0.709981 graduate students 0.515113 phenotypes 0.420428 DAR 0.341157 access permission form 0.755217 project requests 0.50912 Investigators Requesting Authorized 0.770653 interaction 0.333238 access form 0.569266 online 0.337555	CLICK HERE
16647	National Cancer Institute	Html	en	Track 1: Oncology Product Research and Review for M.D. Oncology Fellows	NCI and FDA collaborate to train physicians in clinical trials methodology and medical product development. Learn more about this cancer training program.	cancer treatment 0.479728 product development process 0.567202 review process 0.489003 oncology training programs 0.558331 FDA scientific review 0.54729 permanent residency 0.47764 Medical Center Dr 0.53143 application guidelines 0.474013 continued clinical activities 0.563939 research goals 0.484402 clinical trials methodology 0.592427 post-marketing surveillance 0.480689 Regulatory Review Fellowships 0.542695 Cancer Training 0.476448 wide variety 0.47699 basic science 0.47529 clinical research 0.572543 clinical pharmacology 0.56636 clinical aspects 0.565731 Review list 0.477947 application materials 0.475814 regulatory pathways 0.4862 U.S. citizenship 0.479791 practical experience 0.477134 cancer product development 0.582309	earliest start date 0.532518 regulatory aspects 0.552684 critical ethical issues 0.546923 medical product development 0.68682 product research 0.503682 board eligibility 0.486187 product development research 0.56952 internal medicine 0.479825 clinical trial design 0.90418 oncology subspecialty 0.512496 new product development 0.559224 epidemiology 0.43097 product development 0.772741 senior member 0.472136 radiation oncology 0.485841 human research subjects 0.561696 Clinical training 0.523355 course work 0.477251 drug regulation 0.476113 basic bench science 0.561571 Personal statement 0.473214 Office Phone 0.471769 NCI-FDA Research 0.483426 new agents 0.475146	CLICK HERE